BIO:ON Insight #16 · Sep 15, 2026
Same word, "success" — not the same grade of evidence
Summit and Akeso's ivonescimab beats Keytruda on final overall survival at WCLC in Seoul, AstraZeneca's oral SERD wins FDA approval despite a negative advisory vote, and oral Wegovy resolves obesity in 40% of teens. Same word, "success": three very different grades of evidence.
What I learned this week
If there's one line for this week, it's this: same word, "success" — not the same grade of evidence. We've followed the Keytruda story for three issues now, from #13 onwards, and the time it took to get from an interim readout to final OS feels like the true speed of this industry. Next time you see "approved" or "success," look once more at what evidence sits behind it. See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- Clinical Trials
Summit and Akeso's ivonescimab tops Keytruda on final overall survival
Summit TherapeuticsAkesoivonescimabKeytruda
- FDA Approvals
FDA approves AstraZeneca's camizestrant despite a negative advisory vote
AstraZenecacamizestrantUS FDA
- Clinical Trials
Novo Nordisk's oral Wegovy in an adolescent obesity Phase 3
Novo NordiskWegovy
AI summary
- 1Summit and Akeso's ivonescimab beat Keytruda on final overall survival in lung cancer, presented at WCLC in Seoul.
- 2The FDA approved AstraZeneca's oral SERD camizestrant for breast cancer despite a negative advisory vote.
- 3Novo Nordisk's oral Wegovy resolved obesity in 40% of adolescents, extending its pediatric pipeline.
Relevant rolesClinical developmentRegulatory affairsMedical affairs
Summary and tags generated by AI from the issue text.
References
- 1.Summit and Akeso's ivonescimab tops Keytruda on final overall survival (opens in a new tab)
Fierce Pharma, Sep 13, 2026
- 2.FDA's surprise approval of AstraZeneca's oral SERD sets a new paradigm (opens in a new tab)
Fierce Biotech / BioSpace, Sep 8, 2026
- 3.Oral Wegovy helps free 40% of teens from obesity in Phase 3 trial (opens in a new tab)
Fierce Pharma, Sep 8, 2026
Related insights
Other issues covering the same companies, drugs or topics
Nobody was supposed to clear that wall. Someone did, this week.
Roche bets up to $2.5B on Hanmi's muscle-sparing obesity drug, Regenxbio's gene therapy refiling hits an FDA hold, and Akeso's bispecific beats Keytruda head-to-head. Nobody was supposed to clear that wall. Someone did.
Shared: US FDA, Akeso, ivonescimab, Keytruda
Europe opens the door, China half-closes its own
Lilly's Foundayo weight-loss pill clears Europe's key hurdle, Beijing floats a ban on foreign takeovers of its biotech platforms, and AbbVie and BMS join the 340B court fight. When the rules change, so does the way you win.
Shared: Novo Nordisk, Wegovy, AstraZeneca